Eli Lilly on Friday mentioned it’s investing one other $5.3 billion in a producing plant in Lebanon, Indiana, to spice up provide of its extremely common weight reduction drug Zepbound, diabetes therapy Mounjaro and different medicines.

Demand for these therapies has far outpaced provide over the previous 12 months, spurring shortages within the U.S. and forcing the pharmaceutical large to speculate closely to scale up its manufacturing.

That new dedication brings Eli Lilly’s complete funding on the web site to $9 billion. That makes it Eli Lilly’s largest manufacturing funding in its almost 150-year historical past, the corporate’s CEO David Ricks mentioned in a press release.

Eli Lilly expects the Lebanon web site to start out making medicines towards the top of 2026, and scale up operations via 2028. The corporate first introduced its plans to construct new Indiana websites in 2022. 

The plant will particularly improve Eli Lilly’s capability to fabricate the energetic ingredient in Zepbound and Mounjaro, referred to as tirzepatide. The corporate refers to these therapies as incretin medicine, which mimic sure intestine hormones to suppress an individual’s urge for food and regulate blood sugar. 

“This multi-site campus will make our newest medicines, together with Zepbound and Mounjaro, assist pipeline development and leverage the newest know-how and automation for optimum effectivity, security and high quality management,” Ricks mentioned in a press release.

Eli Lilly mentioned 900 staff, together with engineers, scientists, working personnel and lab technicians, will employees the location when it’s totally operational.

The corporate has spent greater than $18 billion to construct, develop and buy manufacturing vegetation within the U.S. and Europe since 2020.

Eli Lilly has a number of manufacturing websites both “ramping up or beneath building,” Chief Monetary Officer Anat Ashkenazi instructed buyers throughout an earnings name final month. That features the Lebanon plant and one other Indiana web site, two places in North Carolina, one in Eire, one in Germany and a seventh web site the corporate not too long ago acquired from Nexus Prescribed drugs. 

Buyers cheered Eli Lilly after the corporate hiked its full-year income outlook by $2 billion, partly as a consequence of confidence about elevated manufacturing of Zepbound, Mounjaro and different incretin medicine for the remainder of the 12 months.

“Now that we’re 4 months into the 12 months, we’ve better visibility into that, into these nodes of capability and really feel extra assured,” Ashkenazi mentioned through the name.